License and Distribution Agreement Sample Contracts

RECITALS
License and Distribution Agreement • May 21st, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Pennsylvania
AutoNDA by SimpleDocs
THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • June 17th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus

This License and Distribution Agreement (this “Agreement”), dated as of June 14, 2022 (“Effective Date”), is by and between by and between Quoin Pharmaceuticals, Inc., a Delaware corporation located at 42127 Pleasant Forest Court, Ashburn, VA 20148 (“Quoin”) and WINHEALTH INVESTMENT (HK) LIMITED, a company incorporated under the laws of Hong Kong located at Unit 2512, 25/F., Seapower Tower, Concordia Plaza, No.1 Science Museum Road, Kowloon, Hong Kong (“DISTRIBUTOR”) (“Licensee”). Quoin and Licensee are sometimes referred to herein individually as a “Party,” and together as the “Parties.”

LICENSE AND DISTRIBUTION AGREEMENT (MANUFACTURING RIGHTS) (2005 - 2007)
License and Distribution Agreement • April 15th, 2004 • Navarre Corp /Mn/ • Wholesale-computers & peripheral equipment & software • California
EX-10.1 2 dex101.htm LICENSE AND DISTRIBUTION AGREEMENT LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • May 5th, 2020 • California

THIS LICENSE AND DISTRIBUTION AGREEMENT (the “Agreement”) is made and dated as of this 8th day of August, 2006 (the “Effective Date”) by and among BIOLASE Technology, Inc., a Delaware corporation (the “Company”) and Henry Schein, Inc., a Delaware corporation (the “Distributor”) with reference to the following facts:

AMENDMENT NUMBER 2 TO THE LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

between GW PHARMA LIMITED (“GW”) having its registered office at Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ and BAYER HEALTHCARE AG, Division Pharma, having its registered office at Bayerwerk, 51368 Leverkusen, Germany (“Bayer”)

AMENDMENT NUMBER 4 TO THE LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

between GW PHARMA LIMITED (“GW”) having its registered office at Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ and BAYER HEALTHCARE AG, Division Pharma, having its registered office at Bayerwerk, 51368 Leverkusen, Germany (“Bayer”)

BACKGROUND
License and Distribution Agreement • April 20th, 2005 • Valera Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • June 16th, 2015 • BioCardia, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS LICENSE AND DISTRIBUTION AGREEMENT (the “Agreement”) is effective as of October 30, 2012 (the “Effective Date”) by and between BIOMET BIOLOGICS, LLC, a corporation organized and existing under the laws of the State of Indiana, having a place of business at 56 East Bell Drive, Warsaw, Indiana 46582 (“Biomet”) and BIOCARDIA, INC., a Delaware corporation with its principal place of business at 125 Shoreway Road, Suite B, San Carlos, CA 94070 (“BioCardia”). BioCardia and Biomet may be referred to individually as a “Party” or collectively as the “Parties.”

LICENSE AND DISTRIBUTION AGREEMENT between CHIESI FARMACEUTICI S.p.A. and CORNERSTONE THERAPEUTICS INC. Dated May 6, 2009
License and Distribution Agreement • June 26th, 2009 • Cornerstone Therapeutics Inc • Pharmaceutical preparations

This LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made as of this 6th day of May, 2009 (the “Effective Date”) between Chiesi Farmaceutici S.p.A. a company incorporated under the laws of Italy, with its principal place of business at Via Palermo 26/A, 43100 Parma, Italy (“Chiesi”) and Cornerstone Therapeutics Inc. a corporation incorporated under the laws of Delaware, with its principal place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, USA (“Cornerstone”, and together with Chiesi, the “Parties”, each a “Party”).

EX-4.25 2 dex425.htm XYREM LICENSE AND DISTRIBUTION AGREEMENT DATED AS OF OCTOBER 29 CONFIDENTIAL EXECUTION VERSION
License and Distribution Agreement • May 5th, 2020 • New York

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN * .

EX-10.37 2 dex1037.htm LICENSE AND DISTRIBUTION AGREEMENT Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[* * *]” and has been filed separately with the Securities and Exchange Commission pursuant to a...
License and Distribution Agreement • May 5th, 2020 • Massachusetts

This License and Distribution Agreement (this “Agreement”) made as of the 29th day of July, 2003 by and between Keurig, Incorporated, a Delaware corporation with its principal executive offices located at 101 Edgewater Drive, Wakefield, Massachusetts 01880 (“Keurig”), and Diedrich Coffee, Inc., a Delaware corporation with its principal executive offices located at 2144 Michelson Drive, Irvine, CA 92612 (“Diedrich”) Diedrich amends and restates the License Agreement between Keurig and Diedrich dated as of March 13, 2000.

Amendment # 5
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

to the License and Distribution Agreement by and between Bayer Schering Pharma AG (formerly “Bayer AG, Bayer HealthCare, Division Pharma”) and GW Pharma Limited dated May 20, 2003 — hereinafter referred to as “Distribution Agreement” —

CONFIDENTIAL GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • February 3rd, 2011 • BG Medicine, Inc. • Services-medical laboratories • Delaware

This GALECTIN -3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of December 14, 2010 (the “Effective Date”), by and between Siemens Healthcare Diagnostics Inc, a corporation of the state of California, having its principal place of business at 511 Benedict Avenue, Tarrytown, NY 10591 (“SIEMENS”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610N Lincoln Street, Waltham, MA 02451 (“BGM”).

AMENDMENT NUMBER 3 TO THE LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

between GW PHARMA LIMITED (“GW”) having its registered office at Porton Down Science Park, Salisbury, Wiltshire SP4 OJQ and BAYER HEALTHCARE AG, Division Pharma, having its registered office at Bayerwerk, 51368 Leverkusen, Germany (“Bayer”)

LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • June 14th, 2004 • Archipelago Holdings L L C • Security & commodity brokers, dealers, exchanges & services • Illinois

AGREEMENT, dated as of January 7, 1999 (the “Effective Date”), by and between ARCHIPELAGO HOLDINGS, L.L.C., a Delaware limited liability company with its principal offices at 100 South Wacker Drive, Suite 2060, Chicago, IL 60606 (“Archipelago”), and TOWNSEND ANALYTICS, LTD., an Illinois corporation with its principal offices at 100 South Wacker Drive, Suite 2040, Chicago, Illinois 60606 (“TAL”).

BAYER AG and GW PHARMA LTD LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

THIS LICENSE AND DISTRIBUTION AGREEMENT (hereinafter “Agreement”), is made as of the 20th day of May 2003, between GW PHARMA LIMITED (“GW”) having its registered office at Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ and BAYER AG, Bayer HealthCare, Division Pharma, having its registered office at Bayerwerk, 51368 Leverkusen, Germany (“Bayer”).

LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • July 2nd, 2004 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations

THIS LICENSE AND DISTRIBUTION AGREEMENT (the “Agreement”), effective as of March 26, 2004 (the “Effective Date”) is entered into by and between Auxilium Pharmaceuticals, Inc. (“Auxilium”), a company incorporated under the laws of Delaware with offices at 160 W. Germantown Pike, Norristown, PA 19401, USA, and Ipsen Farmaceutica B.V. (“Ipsen”), a company incorporated under the laws of The Netherlands having a registered office at Hoofdweg Oostzijde 620, NL-2132 MJ Hoofddorp.

AutoNDA by SimpleDocs
AMENDED AND RESTATED XYREM LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • New York

This AMENDED AND RESTATED LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of June 30, 2006 (“Execution Date”), by and between Jazz Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3180 Porter Drive, Palo Alto, California 94304, USA (together with its Affiliates, “Jazz Pharmaceuticals”), and UCB Pharma Limited, a company organized under the laws of England having its principal place of business at 208 Bath Road, Slough, Berkshire, SL1 3WE (together with its Affiliates, “UCB”).

LICENSE AND DISTRIBUTION AGREEMENT THIS AGREEMENT made as of the 19th day of July, 1999 BETWEEN:
License and Distribution Agreement • November 12th, 2004 • AccelRate Power Systems Inc. • British Columbia

Petrovic is the legal and beneficial owner of all right, title and interest in and to the Invention, the Patents, the Technology and the Petrovic Marks;

LICENSE AND DISTRIBUTION AGREEMENT Between WEBZEN INC. and NHN USA INC.
License and Distribution Agreement • November 20th, 2009 • Webzen Inc • Services-business services, nec

This LICENSE AND DISTRIBUTION AGREEMENT (“Agreement”) is entered into this May 19, 2008 (hereinafter referred to as “Execution Date”) by and between WEBZEN Inc., a corporation duly organized and existing under the laws of the Republic of Korea (“Korea”) and having its principle office at 6F Daelim Acrotel, 467-6 Dogok-Dong, Kangnam-Gu, Seoul 135-971, Korea (hereinafter referred to as “WEBZEN” or “Licensor”), and NHN USA Inc., organized and existing under the laws of the State of Delaware, USA and having its registered office at 3353 Michelson Dr. Suite 250, Irvine, California 92612, USA (hereinafter referred to as “Licensee”). WEBZEN and Licensee are hereinafter referred individually as a “Party” and collectively as the “Parties”.

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. OMITTED INFORMATION IS INDICATED BY AN ASTERIK (*) AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
License and Distribution Agreement • December 2nd, 2011 • Michael Kors Holdings LTD • Wholesale-apparel, piece goods & notions • New York

LICENSE AND DISTRIBUTION AGREEMENT made as of this 1st day of April 2011, by and between MICHAEL KORS, L.L.C., a limited liability company existing under and by virtue of the laws of the State of Delaware, with offices at 11 West 42nd Street, New York, NY, 10036, USA (“Licensor”) and Michael Kors (HK) Limited, a Hong Kong limited company with offices at 12/F Novel Industrial Building, 850-870 Lai Chi Kok Road, Cheung Sha Wan, Kowloon, Hong Kong (“Licensee”).

CONFIDENTIAL GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • August 31st, 2010 • BG Medicine, Inc. • Services-medical laboratories • Delaware

This GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of November 11, 2009 (the “Effective Date”), by and between Abbott Laboratories, a corporation of the state of Illinois, having its principal place of business at 100 Abbott Park Road, Abbott Park, IL 60064-3500 (“Abbott”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North Waltham, MA 02451 (“BGM”).

AMENDMENT NUMBER 1 TO THE LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • March 26th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations

between GW PHARMA LIMITED (“GW”) having its registered office at Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ and BAYER HEALTHCARE AG, Division Pharma, having its registered office at Bayerwerk, 51368 Leverkusen, Germany (“Bayer”)

LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • January 10th, 2024 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This License and Distribution Agreement (this “Agreement”) is made and entered into as of January 5, 2024, by and between NovaBay Pharmaceuticals, Inc., a Delaware corporation having a principal place of business located at 2000 Powell Street, Suite 1150, Emeryville, California 94608 (“Licensor”), and Sonoma Pharmaceuticals, Inc., a Delaware corporation having a place of business at 5445 Conestoga Court, Unit 150, Boulder, Colorado 80301 (“Licensee”), and (collectively, the “Parties,” or each, individually, a “Party”).

LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • August 14th, 2007 • Document Security Systems Inc • Services-computer integrated systems design • New York

This License and Distribution Agreement (this “Agreement”) is entered into as of this 27th day of June, 2007 (the “Effective Date”) by and between Document Security Systems, Inc., a corporation organized and existing under the laws of the State of New York (“DSS”), and Cultura Interactiva S.A. de C.V., a company organized and existing under the laws of Mexico (“Licensee”).

EXCLUSIVE RAGNAROK ONLINE LICENSE AND DISTRIBUTION AGREEMENT
License and Distribution Agreement • June 1st, 2010 • GRAVITY Co., Ltd. • Services-business services, nec

This License Agreement (hereinafter referred to as “Agreement”) is made and entered into on this 5th day of March, 2010, (hereinafter referred to as “Effective Date”), by and between Gravity Co., Ltd., a corporation duly organized and existing under the laws of the Republic of Korea (hereinafter referred to as “Korea”) and having its principle office at 15F, Nuritkum Square Business Tower, 1605, Sangam-Dong, Mapo-Gu, Seoul, Korea (hereinafter referred to as “Licensor”), and Asiasoft Corporation Public Co.,Ltd., a corporation duly organized and existing under the laws of Thailand and having its principal office at 9 U.M. Tower, 28th Floor, Room 9/283-5, Ramkhamhaeng Road, Suanluang, Bangkok 10250, Thailand (hereinafter referred to as “Licensee”).

LICENSE AND DISTRIBUTION AGREEMENT between MEDIFOCUS INC and MEDIFOCUS HOLDING LIMITED (BVI)
License and Distribution Agreement • September 17th, 2014 • Medifocus Inc. • Surgical & medical instruments & apparatus • Maryland

This LICENSE AND DISTRIBUTION AGREEMENT is effective as of the 8th day of November 2013, by and between MEDIFOCUS INC, an Ontario, Canada corporation having a principal place of business at 10240 Old Columbia Road Suite G Columbia, Maryland U.S.A. 21046 (“Medifocus”), and Medifocus Holding Limited, a Company incorporated in the British Virgin Islands, having a registered address at Akara Building, 24 De Castro Street, Wickhams Cay 1, Road Town, Tortola, British Virgin Islands (“JV”).

License and Distribution Agreement
License and Distribution Agreement • July 17th, 2014 • Dutch Gold Resources Inc • Wholesale-chemicals & allied products • Nevada

This License Agreement (this "Agreement") is made effective as of June 27, 2014 between Dutch Gold Resources, Inc., of 3344 Peachtree Road, Atlanta, Georgia 30326 and Abba Medix Corporation of 1773 Bayly Street Pickering, Ontario, Canada L1W 2Y7.

MolMed and Megapharm enter into a license and distribution agreement for Zalmoxis® in Israel
License and Distribution Agreement • April 28th, 2017

Milan (Italy), April 28, 2016 – MolMed S.p.A. (“MolMed”) and Megapharm Ltd (“Megapharm”) today announce they signed a distribution and license agreement which defines all terms and conditions for the supply, registration, promotion and distribution of Zalmoxis in Israel, as anticipated on December 1, 2016, when the companies signed a term sheet defining the main terms and conditions.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!